A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future …
A Freitag, G Sarri, A Ta, L Gurskyte, D Cherepanov… - …, 2024 - Springer
Abstract Background and Objective Multiple myeloma is a rare incurable hematological
cancer in which most patients relapse or become refractory to treatment. This systematic …
cancer in which most patients relapse or become refractory to treatment. This systematic …
Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo
S Dong, K Hu, Y Shi, G Wang, D Yu, Y Zhao… - Bioorganic & Medicinal …, 2024 - Elsevier
Natural product cantharidin can inhibit multiple myeloma cell growth in vitro, while serious
adverse effects limited its clinical application. Therefore, the structural modification of …
adverse effects limited its clinical application. Therefore, the structural modification of …
Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers
Abstract Background and Objective This study aimed to assess the cost-effectiveness of two
regimens regarded as the standard of care for the treatment of newly diagnosed, transplant …
regimens regarded as the standard of care for the treatment of newly diagnosed, transplant …